Venetoclax With Chemotherapy: Promising for Elderly Patients With AML?
Combined with chemotherapy, venetoclax appears to be effective for treating AML among fit elderly patients.
Leukemia
Survivors of Adolescent, Young Adult ALL May Suffer Late Effects
Estimated 10-year cumulative incidence high for subsequent endocrine disease, cardiac disease.
Identifying Risk Factors for Invasive Fungal Infection in Ibrutinib-Treated CLL Patients
Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.
Sorafenib Maintenance Therapy After Allo-HSCT Improves Outcomes in FLT3-ITD–Positive AML
Among patients with FLT3-internal tandem repeats, sorafenib maintenance therapy reduces the risk of relapse and death after allo-HSCT.
Genetic Prognostic Factors in CLL Treated With Novel Compounds
Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.
Dental Screenings Prior to Induction Chemotherapy for Acute Myeloid Leukemia
Researchers found that identifying and treating acute odontogenic disease before induction chemotherapy prevented infectious dental emergencies in AML patients.
Allogeneic-HSCT Outcomes With Varied Donor Sources in Adult T-Cell Leukemia/Lymphoma
Researchers studied the pros and cons of transplantation from different donor sources to enhance overall outcomes of allo-HSCT in adults with T-cell malignancies.
AEs From Ibrutinib in Real-World CLL: More Research Needed
Some tyrosine kinase inhibitors may cause a hyperinflammatory response.
Risk-Adapted Therapy Prevents Fungal Infections in Childhood Leukemia
Risk-adapted therapy effectively prevents fungal infections and reduces neurotoxicity in children with leukemia.
Subset of Patients With Richter Syndrome May Obtain Long-Term Survival
Data from Spain add to the knowledge of Richter syndrome.
-
Loading...
-
Loading...
Next post in Leukemia
